Sorafenib Relapase Prophylaxis After HCT With PTBCy Regimen

This study tests whether sorafenib — a targeted cancer drug — can prevent blood cancer from coming back in high-risk patients who have just received a stem cell transplant (where healthy blood stem cells from a donor are used to replace diseased ones). The transplant in this study uses a special regimen that includes bendamustine and cyclophosphamide. Researchers want to see if starting sorafenib early after transplant reduces the chance of relapse. **You may be eligible if...** - You received an allogeneic (donor) stem cell transplant using bendamustine and cyclophosphamide as part of your conditioning - You have a high-risk blood cancer like AML or MDS that met specific high-risk criteria - You are in blood cancer remission after the transplant engrafted - You are within the first 100 days after your transplant **You may NOT be eligible if...** - Your cancer relapsed and was successfully treated between transplant and enrollment - You have moderate or severe heart disease, recent heart attack, or stroke - You have severely impaired lung, liver, kidney, or other organ function - You have an active uncontrolled infection - You are pregnant Talk to your doctor to see if this trial is right for you.